Table 1

Description of patients and controls

RA

OA

ReA

PsA

AS

SSc

SLE

Control


Number

98

58

13

30

30

40

56

97

Gender

(F:M)

72:26

29:29

5:8

19:11

5:25

27:13

48:8

64:33

Age *

(years)

55

(23-85)

56

(36-65)

29

(17-60)

48

(23-70)

41

(22-75)

54

(16-77)

42

(17-75)

45

(23-74)

Disease duration (years)

7.9

(0.8-39)

Not available

0.04

(0-0.19)

6.3

(1.7-23.3)

15.6

(0.2-55.2)

1.5

(0.5-19)

5.0

(0.35)

Not applicable

COMP-C3b

(AU)

0.42

(0.19-1.19)

0.58

(0.27-1.36)

0.74

(0.38-1.14)

0.31

(0.19-0.92)

0.33

(0.18-0.51)

0.76

(0.15-1.43)

0.50

(0.27-0.85)

0.20

(0.09-0.83)

COMP

(U/L)

9.1

(3.3-24.4)

11.2

(6.4-22.1)

8.9

(4.4-11.2)

8.2

(4.1-15.3)

6.8

(3.4-12.4)

10.5

(2.3-29.0)

5.6

(3.0-13.3)

7.0

(3.2-12.1)

CRP

(mg/L)

15.5

(0-126)

< 5

(< 5-15)

Not determined

9.3

(1-205)

7.9

(0-65)

12

(0.6-91)

Not

determined

Not determined

ESR

(mm/h)

29

(2-110)

6

(1-35)

48

(2-100)

18

(4-95)

14

(2-64)

18

(2-90)

Not

determined

Not

determined

TNF-α inhibitor

infliximab/etanercept/adalimumab

98/0/0

22/6/2

9/15/6


*Values denote median and range, except for gender and tumor necrosis factor (TNF)-α inhibitor. AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; OA, osteoarthritis; ReA, reactive arthritis; SLE, systemic lupus erythematosus SSc, systemic sclerosis.

Happonen et al. Arthritis Research & Therapy 2012 14:R15   doi:10.1186/ar3694

Open Data